These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11271341)

  • 21. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.
    Jain A; Reyes J; Kashyap R; Rohal S; Abu-Elmagd K; Starzl T; Fung J
    Ann Surg; 1999 Sep; 230(3):441-8; discussion 448-9. PubMed ID: 10493490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of FK 506 in living-related liver transplantation.
    Satomura K; Ozaki N; Okajima H; Egawa H; Uemoto S; Inomata Y; Tanaka K; Yamaoka Y; Hashida T; Yasuhara M; Inui K
    Transplant Proc; 1996 Apr; 28(2):1005. PubMed ID: 8623209
    [No Abstract]   [Full Text] [Related]  

  • 24. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
    Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One hundred children treated with tacrolimus after primary orthotopic liver transplantation.
    McDiarmid S; Goss J; Seu P; Shackleton C; Vargas J; Ament M; Busuttil R
    Transplant Proc; 1998 Jun; 30(4):1397-8. PubMed ID: 9636564
    [No Abstract]   [Full Text] [Related]  

  • 26. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation.
    Kokado Y; Takahara S; Kyo M; Ichimaru N; Toki K; Wang JD; Okuyama A
    Transplant Proc; 1999; 31(1-2):1151-4. PubMed ID: 10083515
    [No Abstract]   [Full Text] [Related]  

  • 27. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
    Bahra M; Neumann UP; Jacob D; Langrehr JM; Neuhaus P
    Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial.
    Langrehr JM; Klupp J; Junge G; Jonas S; Neuhaus R; Bechstein WO; Neuhaus P
    Transplant Proc; 2001 May; 33(3):2330-1. PubMed ID: 11377549
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti-lymphocyte therapy successfully controls late "cholestatic" rejection in pediatric liver transplant recipients.
    Kerkar N; Morotti RA; Iyer K; Arnon R; Miloh T; Sturdevant M; Suchy F; Florman S; Emre S
    Clin Transplant; 2011; 25(6):E584-91. PubMed ID: 21919961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of basiliximab induction therapy in adult-to-adult living-related transplantation and deceased donor liver transplantation: a comparative retrospective analysis of a single-center series.
    Viganò J; Gruttadauria S; Mandalà L; Petridis I; Cintorino D; Li Petri S; Varotti G; Minervini M; Volpes R; Biondo D; Vizzini G; Marsh WJ; Marcos A; Gridelli B
    Transplant Proc; 2008; 40(6):1953-5. PubMed ID: 18675099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Steroid withdrawal in tacrolimus (FK506)-treated pediatric liver transplant recipients.
    McKee M; Mattei P; Schwarz K; Wise B; Colombani P
    J Pediatr Surg; 1997 Jul; 32(7):973-5. PubMed ID: 9247215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients.
    Marino IR; Doria C; Scott VL; Foglieni CS; Lauro A; Piazza T; Cintorino D; Gruttadauria S
    Transplantation; 2004 Sep; 78(6):886-91. PubMed ID: 15385809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.
    Klupp J; Bechstein WO; Pratschke J; Tullius SG; Gebhard A; Lobeck H; Langrehr JM; Neuhaus R; Neuhaus P
    Transplant Proc; 1998 Jun; 30(4):1443-4. PubMed ID: 9636585
    [No Abstract]   [Full Text] [Related]  

  • 34. Lower tacrolimus trough levels in the late period after living donor liver transplantation contribute to improvements in long-term clinical outcomes.
    Geng L; Wang LD; Huang JJ; Shen T; Wang ZY; Lin BY; Ye YF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):204-209. PubMed ID: 29807766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation.
    Gruttadauria S; Vasta F; Mandalà L; Cintorino D; Piazza T; Spada M; Verzaro R; Gridelli B
    Transplant Proc; 2005; 37(6):2611-3. PubMed ID: 16182762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus.
    Jain A; Kashyap R; Marsh W; Rohal S; Khanna A; Fung JJ
    Transplantation; 2001 Apr; 71(8):1102-6. PubMed ID: 11374410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression.
    Jordan ML; Chakrabarti P; Luke P; Shapiro R; Vivas CA; Scantlebury VP; Fung JJ; Starzl TE; Corry RJ
    Transplantation; 2000 Jan; 69(2):265-71. PubMed ID: 10670637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatric renal transplantation under tacrolimus-based immunosuppression.
    Shapiro R; Scantlebury VP; Jordan ML; Vivas C; Ellis D; Lombardozzi-Lane S; Gilboa N; Gritsch HA; Irish W; McCauley J; Fung JJ; Hakala TR; Simmons RL; Starzl TE
    Transplantation; 1999 Jan; 67(2):299-303. PubMed ID: 10075598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients.
    Kliem V; Schaumann D; Ehlerding G; Eberhard OK; Lufft V; Schlitt HJ; Pichlmayr R; Koch KM; Brunkhorst R
    Transplant Proc; 1997 Nov; 29(7):2955-7. PubMed ID: 9365627
    [No Abstract]   [Full Text] [Related]  

  • 40. Conversion to tacrolimus after liver transplantation.
    Jonas S; Bechstein WO; Lemmens HP; Kling N; Grauhan O; Lobeck H; Neuhaus P
    Transpl Int; 1996; 9(1):23-31. PubMed ID: 8748407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.